“While ‘reversal’ of warfarin with vitamin K and clotting factors does not seem to offer much benefit once a patient suffers an intracranial hemorrhage, there is continued optimism that rapid and highly effective antidotes to the NOACs may improve outcomes in these patients,” Dr. Ruff, who was not involved in the study, told Reuters Health by email.
The study had no commercial funding. Some of the authors reported ties to drug companies selling NOACs.
Pages: 1 2 | Single Page
Loading ...
No Responses to “Intracerebral Hemorrhage Outcome Doesn’t Differ by Anticoagulant”